Therefore, in the United States, the Food and Drug Administration (FDA) has approved pembrolizumab monotherapy for patients with recurrent, locally advanced or metastatic ESCC expressing PD‐L1 (CPS ≥ 10), after 1 or more prior lines of systemic therapy in July 2019. Here, CD274 is linked to esophageal squamous cell carcinoma.